ATE258560T1 - Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden - Google Patents
Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) bindenInfo
- Publication number
- ATE258560T1 ATE258560T1 AT97906403T AT97906403T ATE258560T1 AT E258560 T1 ATE258560 T1 AT E258560T1 AT 97906403 T AT97906403 T AT 97906403T AT 97906403 T AT97906403 T AT 97906403T AT E258560 T1 ATE258560 T1 AT E258560T1
- Authority
- AT
- Austria
- Prior art keywords
- mcp
- receptor
- antibodies
- ccr2
- monocyte
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9600820A SE9600820D0 (sv) | 1996-03-01 | 1996-03-01 | Antibodies and their use |
PCT/SE1997/000342 WO1997031949A1 (en) | 1996-03-01 | 1997-02-27 | Antibodies binding to monocyte chemoattractant protein 1 (mcp-1) receptor (ccr2) |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE258560T1 true ATE258560T1 (de) | 2004-02-15 |
Family
ID=20401642
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97906403T ATE258560T1 (de) | 1996-03-01 | 1997-02-27 | Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden |
Country Status (11)
Country | Link |
---|---|
US (1) | US6084075A (de) |
EP (1) | EP0914345B1 (de) |
JP (1) | JP2000510685A (de) |
AT (1) | ATE258560T1 (de) |
AU (1) | AU724037B2 (de) |
DE (1) | DE69727382T2 (de) |
DK (1) | DK0914345T3 (de) |
ES (1) | ES2210496T3 (de) |
PT (1) | PT914345E (de) |
SE (1) | SE9600820D0 (de) |
WO (1) | WO1997031949A1 (de) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE347594T1 (de) | 1994-01-13 | 2006-12-15 | Univ California | Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung |
US20020019026A1 (en) * | 1995-06-05 | 2002-02-14 | Daniel R. Soppet | Human g-protein receptor hgber32 |
GB9705521D0 (en) * | 1997-03-18 | 1997-05-07 | Univ Sheffield | The use of mononuclear phagocytes in the vivo imaging of hypoxic/ischaemic tissue |
EP1002081B1 (de) * | 1997-08-14 | 2006-06-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Verzögerter fortschritt von aids durch missense allel des ccr2 gens |
ES2368823T3 (es) * | 1998-01-26 | 2011-11-22 | Genentech, Inc. | Anticuerpos del receptor 4 de muerte (dr4) y usos de los mismos. |
WO2001057226A1 (en) * | 2000-02-03 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
US6727349B1 (en) | 1998-07-23 | 2004-04-27 | Millennium Pharmaceuticals, Inc. | Recombinant anti-CCR2 antibodies and methods of use therefor |
US6312689B1 (en) * | 1998-07-23 | 2001-11-06 | Millennium Pharmaceuticals, Inc. | Anti-CCR2 antibodies and methods of use therefor |
US6696550B2 (en) | 1998-07-23 | 2004-02-24 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
US6488930B1 (en) | 1999-01-15 | 2002-12-03 | Millennium Pharmaceuticals, Inc. | Anti-CCR4 antibodies and methods of use therefor |
AU2004208716B2 (en) * | 2000-02-03 | 2007-01-04 | Millennium Pharmaceuticals, Inc. | Humanized anti-CCR2 antibodies and methods of use therefor |
EP1783227A1 (de) * | 2000-02-03 | 2007-05-09 | Millennium Pharmaceuticals, Inc. | Humanisierte Antikörper gegen CCR2 und Verfahren zur deren Verwendung |
AU4574501A (en) | 2000-03-17 | 2001-10-03 | Millennium Pharm Inc | Method of inhibiting stenosis and restenosis |
WO2002072141A2 (en) * | 2001-03-09 | 2002-09-19 | William Herman | Targeted ligands |
DE60216606T2 (de) | 2001-06-07 | 2007-04-05 | Chemocentryx Inc., Mountain View | Zellwanderungsassay |
US7468253B2 (en) | 2001-06-07 | 2008-12-23 | Chemocentryx, Inc. | Method for multiple chemokine receptor screening for antagonists using RAM assay |
US20040151721A1 (en) | 2001-10-19 | 2004-08-05 | O'keefe Theresa | Humanized anti-CCR2 antibodies and methods of use therefor |
US7442512B2 (en) * | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7253007B2 (en) * | 2001-11-30 | 2007-08-07 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7413866B2 (en) * | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
US7871619B2 (en) * | 2001-11-30 | 2011-01-18 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
ATE517855T1 (de) * | 2001-11-30 | 2011-08-15 | Biogen Idec Inc | Antikörper gegen chemotaktische monozytenproteine |
US20050142539A1 (en) * | 2002-01-14 | 2005-06-30 | William Herman | Targeted ligands |
CN101143221A (zh) * | 2002-03-15 | 2008-03-19 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
EP1567555A4 (de) | 2002-11-27 | 2006-06-21 | Biogen Idec Inc | Humanisierte antikörper gegen chemotaktische monozytenproteine |
KR101061352B1 (ko) * | 2002-12-20 | 2011-08-31 | 케모센트릭스 | 인간 종양-발현된 ccxckr2의 저해물질 |
US20050148507A1 (en) * | 2003-05-02 | 2005-07-07 | Boehringer Ingelheim International Gmbh | Method for the production of an N-terminally modified chemotactic factor |
US20100247540A1 (en) * | 2003-10-30 | 2010-09-30 | Chemocentryx, Inc. | Methods and Compositions For Modulating Angiogenesis |
US20080299130A1 (en) * | 2004-05-04 | 2008-12-04 | University Of Kentucky Research Foundation | Methods And Compositions For The Treatment Of Ocular Neovascularization |
WO2006109301A2 (en) * | 2005-04-15 | 2006-10-19 | Rappaport Family Institute For Research In The Medical Sciences | Molecules and methods of using same for treating mcp-1/ccr2 associated diseases |
US7678891B2 (en) * | 2005-04-21 | 2010-03-16 | Chemocentryx, Inc. | Antibodies that bind CCX-CKR2 |
DE102006015341A1 (de) * | 2006-04-03 | 2007-10-04 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts | Behandlung von multipler Sklerose und/oder rheumatoider Arthritis |
US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
JP2010505878A (ja) * | 2006-10-05 | 2010-02-25 | セントコア・オーソ・バイオテツク・インコーポレーテツド | 線維症の処置のためのccr2アンタゴニスト |
EP2321351B1 (de) | 2008-08-18 | 2017-11-01 | Pfizer Inc. | Antikörper gegen ccr2 |
WO2014064192A1 (en) | 2012-10-26 | 2014-05-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment and prediction of myocardial infraction |
WO2016081801A1 (en) * | 2014-11-21 | 2016-05-26 | Millennium Pharmaceuticals, Inc. | Use of an anti-ccr2 antagonist in the treatment of an infectious disease |
US11846629B2 (en) | 2016-09-20 | 2023-12-19 | Tulane University | MonoMac-1 cells expressing CD16 and CD163 |
JP6824689B2 (ja) * | 2016-10-27 | 2021-02-03 | 株式会社ナリス化粧品 | 真皮シミ予防・改善剤及び/又はマクロファージ誘引剤のスクリーニング方法 |
US20180206726A1 (en) | 2016-12-07 | 2018-07-26 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
WO2018112264A1 (en) | 2016-12-14 | 2018-06-21 | Progenity Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
WO2018195283A1 (en) | 2017-04-19 | 2018-10-25 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
WO2019113464A1 (en) | 2017-12-08 | 2019-06-13 | Elstar Therapeutics, Inc. | Multispecific molecules and uses thereof |
WO2020033791A1 (en) | 2018-08-09 | 2020-02-13 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
AU2019346645A1 (en) | 2018-09-27 | 2021-04-29 | Marengo Therapeutics, Inc. | CSF1R/CCR2 multispecific antibodies |
US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
JP7397996B2 (ja) | 2020-11-09 | 2023-12-13 | 武田薬品工業株式会社 | 抗体薬物コンジュゲート |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994011504A1 (en) * | 1992-11-10 | 1994-05-26 | Genentech, Inc. | C-c ckr-1, c-c chemokine receptor |
US5652133A (en) * | 1993-01-28 | 1997-07-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Cloning and expression of the human macrophage inflammatory protein-1.alpha.α) /rantes receptor |
ATE347594T1 (de) * | 1994-01-13 | 2006-12-15 | Univ California | Monocyten protein rezeptoren aus säugern, mit chemoattraktion auslösender wirkung |
DE19503303A1 (de) * | 1995-02-02 | 1996-08-08 | Teves Gmbh Alfred | Filtersystem mit selbsttätigem Filterwechsel für Kraftfahrzeuge |
-
1996
- 1996-03-01 SE SE9600820A patent/SE9600820D0/xx unknown
-
1997
- 1997-02-27 EP EP97906403A patent/EP0914345B1/de not_active Expired - Lifetime
- 1997-02-27 AU AU21104/97A patent/AU724037B2/en not_active Ceased
- 1997-02-27 WO PCT/SE1997/000342 patent/WO1997031949A1/en active IP Right Grant
- 1997-02-27 ES ES97906403T patent/ES2210496T3/es not_active Expired - Lifetime
- 1997-02-27 AT AT97906403T patent/ATE258560T1/de not_active IP Right Cessation
- 1997-02-27 DE DE69727382T patent/DE69727382T2/de not_active Expired - Fee Related
- 1997-02-27 JP JP09530879A patent/JP2000510685A/ja active Pending
- 1997-02-27 DK DK97906403T patent/DK0914345T3/da active
- 1997-02-27 PT PT97906403T patent/PT914345E/pt unknown
- 1997-02-28 US US08/734,171 patent/US6084075A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP0914345A1 (de) | 1999-05-12 |
DK0914345T3 (da) | 2004-05-10 |
JP2000510685A (ja) | 2000-08-22 |
PT914345E (pt) | 2004-05-31 |
DE69727382D1 (de) | 2004-03-04 |
US6084075A (en) | 2000-07-04 |
SE9600820D0 (sv) | 1996-03-01 |
AU2110497A (en) | 1997-09-16 |
EP0914345B1 (de) | 2004-01-28 |
DE69727382T2 (de) | 2004-11-04 |
ES2210496T3 (es) | 2004-07-01 |
AU724037B2 (en) | 2000-09-07 |
WO1997031949A1 (en) | 1997-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE258560T1 (de) | Antikörper die den monozyten chemolockstoff protein 1 (mcp-1) rezeptor (ccr2) binden | |
AU1679395A (en) | Mammalian monocyte chemoattractant protein receptors | |
EP0584136B1 (de) | Bestimmung von peptidmotiven auf mhc-molekülen | |
ATE150977T1 (de) | Markiertes monocyte-chemoattractant- proteinmaterial und medizinische anwendung | |
WO2000078813A3 (en) | Huntington disease cellular model: stably transfected pc12 cells expressing mutant huntingtin | |
BR9508402A (pt) | Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união | |
ATE214943T1 (de) | Therapeutische zusammensetzungen die monoklonale antikörper enthalten gegen den menschlichen rezeptor für epidermalen wachstumsfaktor | |
EP1746160A3 (de) | Hepatozyt-Wachstumsfaktor-Rezeptor-Antagonisten und deren Anwendung | |
DE69736976D1 (de) | Mit Alzheimer Krankheit verknüpften Verfahren zur Diagnose, zur Herstellung von Medikamenten und zum Screenen von Substanzen sowie aus Beta-Amyloid abgeleiteten Peptiden | |
ATE318845T1 (de) | Therapeutische multispezifische verbindungen, die antikörper gegen den fcalpha-rezeptor enthalten | |
DE3750342T2 (de) | Menschliches gamma-interferon-spezifisches Rezeptorprotein, Antikörper gegen dieses Protein, Verfahren zur Herstellung dieses Proteins und dieses Antikörpers und dieses Protein und diesen Antikörper enthaltende Zusammensetzungen. | |
EP2330129A3 (de) | Antikörper gegen TNF, Zusammensetzungen, Verfahren und Verwendungen | |
EP1908837A3 (de) | Menschliche Rezeptorproteine, zugehörige Reagenzien und Verfahren | |
DE69717664D1 (de) | Protein e25a, methoden zu dessen herstellung und anwendung | |
NO971341D0 (no) | Promoter for reseptor tyrosinkinase TIE | |
WO1995019435A3 (en) | T cell antigen receptor v region proteins and methods of preparation thereof | |
CA2207505A1 (en) | Neurological drug screens | |
AU9363398A (en) | Hepatitis c receptor protein cd81 | |
TR200102877T2 (tr) | İmmünoglobulinin kendi yüksek afinite reseptörüne bağlanmasını inhibe eden antikorlara karşı anti-idiotipik antikorlar. | |
CA2366514A1 (en) | Diagnostic and therapeutic use of antibodies against the urokinase receptor | |
ATE248189T1 (de) | Antikörper gegen vasp (vasodilator-stimulated phosphoprotein), hybridomzellen für deren gewinnung, und deren verwendung | |
ATE265533T1 (de) | Saeugetierchemokine | |
AR010333A1 (es) | Una muteina ob, una secuencia de adn, un vector de expresion una celula hospedadora procariota o de mamifero, un baculovirus recombinante, una celulahospedadora, un metodo para la produccion de una muteina ob, una composicion farmaceutica, el uso de una proteina ob para la preparacion de una composi | |
DE69229948D1 (de) | hGPIIb-FRAGMENTE UND IHRE VERWENDUNG IN IN-VITRO-VERFAHREN ZUR BESTIMMUNG VON IN VIVO STATTFINDENDEN THROMBOTISCHEN EREIGNISSEN | |
MXPA03009138A (es) | Produccion de anticuerpos monoespecificos policlonales, contra variantes del receptor activador del plasminogeno de tipo uroquinasa (upar) del4, del5 y del4+5 y su uso para propositos de diagnostico y terapeutico. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 0914345 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |